scholarly journals Clinical significance of non-Hodgkin's lymphoma with an irregular, non-contrast-enhanced area

1997 ◽  
Vol 2 (2) ◽  
pp. 61-66
Author(s):  
Yasuhiro Saitoh ◽  
Masayuki Mineta ◽  
Tomonori Yamada ◽  
Dalhei Yoshikawa ◽  
Hiroshi Yoshida ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Contrast Enhanced ◽  
Non Hodgkin's Lymphoma

Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma

1993 ◽  
Vol 70 (04) ◽  
pp. 568-572 ◽  
Author(s):  
Roberto Stasi ◽  
Elisa Stipa ◽  
Mario Masi ◽  
Felicia Oliva ◽  
Alessandro Sciarra ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Significance ◽  
Antiphospholipid Antibodies ◽  
Myeloid Leukemia ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Tnf Alpha ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Acute Myeloid

SummaryThis study was designed to explore the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) titres in patients affected by acute myeloid leukemia (AML) and highgrade non-Hodgkin’s lymphoma (NHL). We also analyzed possible correlations with circulating levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and the soluble form of the receptor for interleukin-2 (sIL-2r). Nineteen patients with de novo AML and 14 patients with newly-diagnosed NHL were investigated. Tests for APA included the measurement of anticardiolipin antibodies (ACA) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Five patients with AML (26.3%) and 5 patients with NHL (35.7%) presented elevated APA at diagnosis, as compared to 3 of 174 persons of the control group (p <0.0001). APA titres became normal in all patients responding to treatment, whereas nonresponders retained elevated levels. In addition, 6 patients (4 with AML and 2 with NHL), who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or ACA positivity. At presentation, the mean levels of IgG- and IgM-ACA in patients were not significantly different from Controls, and concordance between ACA and LA results reached just 30%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and sIL-2r in NHL were found significantly elevated compared to Controls (p = 0.003, p = 0.009 and p = 0.024 respectively). In addition, the levels of these cytokines correlated with IgG-ACA at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.

Clinical Significance of Monoclonality by Flow Cytometry in Histologically Negative Bone Marrow in Patients with Diffuse B Cell Non Hodgkin’s Lymphoma.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4686-4686
Author(s):  
Meir Lahav ◽  
Michael Lucianski ◽  
Judith Radnay ◽  
Hava Shapiro ◽  
Naomi Gronich ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Flow Cytometry ◽  
B Cell ◽  
Clinical Significance ◽  
Hodgkin’S Lymphoma ◽  
Clinical Course ◽  
Hodgkin's Lymphoma ◽  
Flow Cytometric ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Bone marrow (BM) involvement in diffuse large B cell non Hodgkin’s lymphoma (DLBCL) results in stage IV staging and has negative impact on survival. Up to 40% of patients with DLBCL have BM involvement by routine histology of marrow biopsy. The identification of lymphoid monoclonality is widely used in diagnosis of lymphoma, by flow cytometric and molecular methods. The clinical significance of monoclonality by these methods has not been systematically addressed in clinical setting. An International Workshop of response criteria in non Hodgkin’s lymphoma recommends that histologically normal marrow with small clonal population detected by flow cytometry should be considered normal until there are clinical studies that demonstrate a different outcome for this group. Recently it was reported that clonality detected by PCR amplification carries worse prognosis in patients with DLBCL. In our institution bone marrow biopsies of all patients with lymphoma are routinely evaluated by flow cytometric analysis since 1993. We evaluated the clinical course of all our patients with DLBCL diagnosed or followed up between 1993 and 2004 and compared the clinical course of patients with histologically positive marrow, histologically and cytometry negative marrow and histologically negative marrow and monoclonal lymphoid population detected by flow cytometry. Monoclonality was defined as ration of light chain expression kappa: lambda>3:1 or lambda: kappa > 2:1 in at least 2% of the gated population. Selected cells were analyzed by two or three color combinations: CD5 versus CD19, CD20 versus CD10 and kappa chain versus lambda chain occasionally with the addition of CD19 or CD20. Among 110 patients, 80 had negative marrow histologically and on cytometry (BM-FC-), 16 were positive on both parameters (BM+FC+) and 14 were histologically negative and cytometry positive (BM-FC+). All three groups were similar in parameters as age, performance status, hemoglobin and LDH levels. BM-FC- and BM-FC+ were similar in IPI scores. BM-FC- patients had significantly longer survival time that BM+FC+ and BM-FC+ patients. There was no significant difference in survival of BM+FC+ and BM-FC+ patients. We conclude that the clinical outcome of patients with DLBCL with histologically normal bone marrow and monoclonality on flow cytometry is similar to those with histologically positive marrow. These results may imply that lymphoid monoclonality on flow cytometry should be regarded as bone marrow involvement and treated as such.

Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis

Cancer ◽  
1991 ◽  
Vol 67 (5) ◽  
pp. 1389-1395 ◽  
Author(s):  
Maureen G. Conlan ◽  
James O. Armitage ◽  
Martin Bast ◽  
Dennis D. Weisenburger
Keyword(s):  
Clinical Significance ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Clinical Significance of TIPE2 Protein Upregulation in Non-Hodgkin’s Lymphoma

2016 ◽  
Vol 64 (9) ◽  
pp. 556-564 ◽  
Author(s):  
Chunyan Hao ◽  
Na Zhang ◽  
Minghong Geng ◽  
Qing Ren ◽  
Yan Li ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: Biologic and clinical significance

2000 ◽  
Vol 37 (4) ◽  
pp. 396-411 ◽  
Author(s):  
R. S. K. Chaganti ◽  
Gouri Nanjangud ◽  
Helmut Schmidt ◽  
Julie Teruya-Feldstein
Keyword(s):  
Clinical Significance ◽  
Hodgkin’S Lymphoma ◽  
Chromosomal Abnormalities ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Clinical significance of circulating CD44 in non-Hodgkin's lymphoma

1998 ◽  
Vol 79 (3) ◽  
pp. 221-225 ◽  
Author(s):  
Raija Ristamäki ◽  
Heikki Joensuu ◽  
Hans Hagberg ◽  
Karl M. Kalkner ◽  
Sirpa Jalkanen
Keyword(s):  
Clinical Significance ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma

Leukemia ◽  
2003 ◽  
Vol 17 (1) ◽  
pp. 196-202 ◽  
Author(s):  
N Niitsu ◽  
Y Honma ◽  
K Iijima ◽  
T Takagi ◽  
M Higashihara ◽  
...  
Keyword(s):  
Cell Surface ◽  
Clinical Significance ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document